SUCCESSOR-1: A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Condition: Multiple Myeloma

Sponsor: Celgene Corporation

Full Title
Protocol CA057-001: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)

Study Treatment
1:1 randomization between the following treatment arms:
Arm A: Mezigdomide (modulator of the E3 ubiquitin ligase complex containing cereblon) in combination with Bortezomib and Dexamethasone
Arm B: Pomalidomide, Bortezomib, and Dexamethasone

Eligibility/Info
Relapsed or refractory multiple myeloma that has continued to grow or that has come back after 1-3 prior lines of antimyeloma systemic therapy that included lenalidomide.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage